View Item 

Show simple item record

Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study
dc.contributor.authorLina, Bruno
dc.contributor.authorBoucher, Charles
dc.contributor.authorOsterhaus, Albert
dc.contributor.authorMonto, Arnold S.
dc.contributor.authorSchutten, Martin
dc.contributor.authorWhitley, Richard J.
dc.contributor.authorNguyen‐van‐tam, Jonathan S.
dc.date.accessioned2018-03-07T18:25:17Z
dc.date.available2019-05-13T14:45:24Zen
dc.date.issued2018-03
dc.identifier.citationLina, Bruno; Boucher, Charles; Osterhaus, Albert; Monto, Arnold S.; Schutten, Martin; Whitley, Richard J.; Nguyen‐van‐tam, Jonathan S. (2018). "Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study." Influenza and Other Respiratory Viruses 12(2): 267-278.
dc.identifier.issn1750-2640
dc.identifier.issn1750-2659
dc.identifier.urihttps://hdl.handle.net/2027.42/142507
dc.publisherWiley Periodicals, Inc.
dc.subject.otherantiviral
dc.subject.otherneuraminidase inhibitor
dc.subject.otherresistance
dc.subject.otherinfluenza
dc.titleFive years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMicrobiology and Immunology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142507/1/irv12534_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142507/2/irv12534.pdf
dc.identifier.doi10.1111/irv.12534
dc.identifier.sourceInfluenza and Other Respiratory Viruses
dc.identifier.citedreferenceSheu TG, Deyde VM, Okomoâ Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008; 52: 3284 â 92.
dc.identifier.citedreferenceAoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther. 2007; 12: 603 â 16.
dc.identifier.citedreferenceStephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis. 2009; 48: 389 â 96.
dc.identifier.citedreferenceKiso M, Mitamura K, Sakaiâ Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004; 364: 759 â 65.
dc.identifier.citedreferenceHauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivirâ resistant influenza viruses A (H1N1), Norway, 2007â 08. Emerg Infect Dis. 2009; 15: 155 â 62.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Update: influenza activityâ United States, September 28, 2008â April 4, 2009, and composition of the 2009â 10 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009; 58: 369 â 74.
dc.identifier.citedreferenceMeijer A, Lackenby A, Hungnes O, et al. Oseltamivirâ resistant influenza virus A (H1N1), Europe, 2007â 08 season. Emerg Infect Dis. 2009; 15: 552 â 60.
dc.identifier.citedreferenceRameixâ Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 2008; 4: e1000103.
dc.identifier.citedreferenceWorld Health Organization (WHO). Update on oseltamivirâ resistant pandemic (H1N1) 2009 influenza virus: January 2010. Wkly Epidemiol Rec. 2010; 85: 37 â 48.
dc.identifier.citedreferenceWhitley RJ, Boucher CA, Lina B, et al. Global assessment of resistance to neuraminidase inhibitors, 2008â 2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis. 2013; 56: 1197 â 205.
dc.identifier.citedreferencePozo F, Lina B, Andrade HR, et al., Community Network of Reference Laboratories for Human Influenza in Europe. Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe. J Clin Virol. 2013; 57: 5 â 12.
dc.identifier.citedreferenceMeijer A, Rebeloâ deâ Andrade H, Correia V, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012â 2013. Antiviral Res. 2014; 110: 31 â 41.
dc.identifier.citedreferencevan der Vries E, Anber J, van der Linden A, et al. Molecular assays for quantitative and qualitative detection of influenza virus and oseltamivir resistance mutations. J Mol Diagn. 2013; 15: 347 â 54.
dc.identifier.citedreferenceTashiro M, McKimmâ Breschkin JL, Saito T, et al. Surveillance for neuraminidaseâ inhibitorâ resistant influenza viruses in Japan, 1996â 2007. Antivir Ther. 2009; 14: 751 â 61.
dc.identifier.citedreferenceHurt AC, Besselaar TG, Daniels RS, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014â 2015. Antiviral Res. 2016; 132: 178 â 85.
dc.identifier.citedreferenceHussain M, Galvin HD, Haw TY, Nutsford AN, Husain M. Drug resistance in influenza A virus: the epidemiology and management. Infect Drug Resist. 2017; 10: 121 â 134.
dc.identifier.citedreferenceKiso M, Mitamura K, Sakaiâ Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004; 364: 759 â 65.
dc.identifier.citedreferenceYen HL, Herlocher LM, Hoffmann E, et al. Neuraminidase inhibitorâ resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother. 2005; 49: 4075 â 84.
dc.identifier.citedreferenceOkomoâ Adhiambo M, Demmlerâ Harrison GJ, Deyde VM, et al. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother. 2010; 54: 1834 â 41.
dc.identifier.citedreferenceWetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol. 2003; 41: 742 â 50.
dc.identifier.citedreferenceWang B, Taylor J, Ratnamohan M, et al. Frequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivirâ resistant influenza A(H1N1)pdm09 virus, Australia, June to August 2011. Euro Surveill. 2012; 17: pii: 20210.
dc.identifier.citedreferenceBloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science. 2010; 328: 1272 â 5.
dc.identifier.citedreferenceTewawong N, Prachayangprecha S, Vichiwattana P, et al. Assessing antigenic drift of seasonal influenza A(H3N2) and A(H1N1)pdm09 viruses. PLoS ONE. 2015; 10: e0139958.
dc.identifier.citedreferenceGaymard A, Le Briand N, Frobert E, Lina B, Escuret V. Functional balance between neuraminidase and haemagglutinin in influenza viruses. Clin Microbiol Infect. 2016; 22: 975 â 983.
dc.identifier.citedreferenceHayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis. 2006; 194: S119 â 26.
dc.identifier.citedreferenceKim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent antiâ influenza activity. J Am Chem Soc. 1997; 119: 681 â 90.
dc.identifier.citedreferenceBright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005; 366: 1175 â 81.
dc.identifier.citedreferenceMonto AS, McKimmâ Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother. 2006; 50: 2395 â 402.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
irv12534_am.pdf
Size:
730.7KB
Format:
PDF
View/Open
Name:
irv12534.pdf
Size:
544.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.